RayBio® Human MIP-1 alpha (CCL3) ELISA Kit for cell culture supernatants, Heparin and/or EDTA treated plasma, and serum samples. Citrate is not recommended.
Lead time: Typically ships within 1-2 business days. No Friday shipments.
The entire kit may be stored at -20°C for up to 1 year from the date of shipment. Avoid repeated freeze-thaw cycles. The kit may be stored at 4°C for up to 6 months. For extended storage, it is recommended to store at -80°C.
Schepers, Koen, et al. "Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche." Cell stem cell 13.3 (2013): 285-299.
Wang J., Su X., Yang L., et al. The influence of myeloid-derived suppressor cells on angiogenesis and tumor growth after cancer surgery. Int J Cancer. 2016 Jun 1;138(11):2688-99. doi: 10.1002/ijc.29998.
Lu P., Zheng D., Fang C., et al. Cytokines in cerebrospinal fluid of neurosyphilis patients: Identification of Urokinase plasminogen activator using antibody microarrays. J Neuroimmunol. 2016 Apr 15;293:39-44. doi: 10.1016/j.jneuroim.2015.12.010.
Leow K., Goh W., Heng C. Effect of serum amyloid A1 treatment on global gene expression in THP-1-derived macrophages. Inflamm Res. 2012 Apr;61(4):391-8. doi: 10.1007/s00011-011-0424-4.
Species:
Human
Sample Type:
Conditioned Media (Human THP-1 macrophage cell lines)
Cai D, Xu Y, Ding R, Qiu K, Zhang R, Wang H, Huang L, Xie X, Yan H, Deng Y, Lin X, Shao J, Luo X, Duan C. Extensive serum biomarker analysis in patients with non-small-cell lung carcinoma. Cytokine. 2020 Feb;126:154868. doi: 10.1016/j.cyto.2019.154868. Epub 2019 Oct 16. PMID: 31629110.
Han Z., Li J., Chen Z. Genetic polymorphism of CCL2-2510 and susceptibility to enterovirus 71 encephalitis in a Chinese population. Archives of Virology. 10.1007/s00705-014-2082-7 [Epub ahead of print]
Xue N., Lin J., Xing S., et al. Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA. Cancer Res Treat. 2019 Jan;51(1):378-390. doi: 10.4143/crt.2018.070.